Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in JuneGlobeNewsWire • 06/12/25
Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)Seeking Alpha • 05/14/25
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in JuneGlobeNewsWire • 05/14/25
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/14/25
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 05/13/25
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/13/25
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal BoardGlobeNewsWire • 05/12/25
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in MayGlobeNewsWire • 05/05/25
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 04/28/25
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 03/11/25
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)Seeking Alpha • 03/10/25